aTyr Pharma, Inc.
NASDAQATYR is the week's most dramatic biotech wreckage — a 44% single-day collapse that leaves the stock at $0.53, down 37% on the week and 36% over the past month. The trigger was blunt. On May 11, aTyr Pharma announced a new Phase 3 trial of efzofitimod in pulmonary sarcoidosis, designed after input from an FDA Type C meeting. For a stock that had already suffered a Phase 3 failure in…
Snapshot as of 28 Jun 2026
ATYR is the week's most dramatic biotech wreckage — a 44% single-day collapse that leaves the stock at $0.53, down 37% on the week and 36% over the past month. The trigger was blunt. On May 11, aTyr Pharma announced a…
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for ATYR — free to start on ORTEX.
Sign up for free →Open ATYR on ORTEX